Galectin Therapeutics (GALT) Gains from Investment Securities (2010 - 2026)
Galectin Therapeutics (GALT) recorded quarterly Gains from Investment Securities of $211583.0 in Q1 2026, up 138.86% quarter-over-quarter from $88579.0 in Q4 2025, and up 746.33% on a YoY basis from $25000.0 in Q1 2025.
Galectin Therapeutics (GALT) Gains from Investment Securities (2010 - 2026) Analysis & Trends
Galectin Therapeutics' Gains from Investment Securities history runs 16 years deep, the most recent figure standing at $211583.0 for Q1 2026.
- In Q1 2026, Gains from Investment Securities rose 746.33% year-over-year to $211583.0; the TTM figure through Mar 2026 stood at $211583.0 (down 66.19% YoY), while the FY2025 annual figure was $6.6 million, up 378.7% from the prior year.
- Gains from Investment Securities was $211583.0 for Q1 2026 at Galectin Therapeutics, up from $88579.0 in the prior quarter.
- In the past five years, Gains from Investment Securities ranged from a high of $5.6 million in Q2 2022 to a low of $10000.0 in Q1 2022.
- Historically, Gains from Investment Securities has averaged $601481.1 across 5 years, with a median of $156345.0 in 2023.
- Biggest YoY gain for Gains from Investment Securities was 7590.0% in 2023; the steepest drop was 98.66% in 2023.
- A 5-year view of Gains from Investment Securities shows it stood at $945000.0 in 2022, then slumped by 83.46% to $156345.0 in 2023, then jumped by 92.17% to $300445.0 in 2024, then slumped by 70.52% to $88579.0 in 2025, then surged by 138.86% to $211583.0 in 2026.
- The last three Gains from Investment Securities figures came in at $211583.0 (Q1 2026), $88579.0 (Q4 2025), and $177334.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Galectin Therapeutics | 185.83 Mn | 171.73 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 211,583.00 |
| Mar 31, 2026 | 211,583.00 |
| Dec 31, 2025 | 88,579.00 |
| Dec 31, 2025 | 88,579.00 |
| Sep 30, 2025 | 177,334.00 |
| Sep 30, 2025 | 177,334.00 |
| Jun 30, 2025 | 88,579.00 |
| Jun 30, 2025 | 88,579.00 |
| Mar 31, 2025 | 25,000.00 |
| Mar 31, 2025 | 25,000.00 |
| Dec 31, 2024 | 300,445.00 |
| Dec 31, 2024 | 300,445.00 |
| Sep 30, 2024 | 153,288.00 |
| Sep 30, 2024 | 153,288.00 |
| Jun 30, 2024 | 300,445.00 |
| Jun 30, 2024 | 300,445.00 |
| Dec 31, 2023 | 156,345.00 |
| Dec 31, 2023 | 156,345.00 |
| Sep 30, 2023 | 75,529.00 |
| Sep 30, 2023 | 75,529.00 |